Small Bowel Perforation Secondary to Metastatic Non-small Cell Lung Cancer. A Rare Entity with a Dismal Prognosis

2011 ◽  
Vol 43 (3) ◽  
pp. 391-395 ◽  
Author(s):  
Nikolaos S. Salemis ◽  
Efstathios Nikou ◽  
Christos Liatsos ◽  
Christos Gakis ◽  
Grigorios Karagkiouzis ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Bowel ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Bowel Perforation ◽  
Small Cell ◽  
Rare Entity ◽  
Small Bowel Perforation ◽  
Small Cell Lung ◽  
Dismal Prognosis

scholarly journals Bowel Perforation after Erlotinib Treatment in a Patient with Non-Small Cell Lung Cancer

2011 ◽  
Vol 52 (4) ◽  
pp. 695 ◽  
Author(s):  
Yun-Hong Cheon ◽  
Moon Jin Kim ◽  
Min Gyu Kang ◽  
Hee Jin Kim ◽  
Sang Su Lee ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Bowel Perforation ◽  
Small Cell ◽  
Small Cell Lung

Small Cell Lung Cancer With Life-Threatening Small Bowel Metastasis: A Case Report

2018 ◽  
Vol 113 (Supplement) ◽  
pp. S1396-S1397
Author(s):  
Aynur Rahman ◽  
Tyler Aasen ◽  
Dhara Chaudhari ◽  
Maria Zayko ◽  
Moka Nagaishwarya
Keyword(s):  
Lung Cancer ◽  
Case Report ◽  
Small Bowel ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Small Bowel Metastasis ◽  
Life Threatening

scholarly journals Cisplatin, Irinotecan, and Bevacizumab for Untreated Extensive-Stage Small-Cell Lung Cancer: CALGB 30306, a Phase II Study

2011 ◽  
Vol 29 (33) ◽  
pp. 4436-4441 ◽  
Author(s):  
Neal E. Ready ◽  
Arkadiusz Z. Dudek ◽  
Herbert H. Pang ◽  
Lydia D. Hodgson ◽  
Stephen L. Graziano ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Phase Ii Study ◽  
Bowel Perforation ◽  
Small Cell ◽  
Small Cell Lung ◽  
End Point ◽  
Extensive Stage

Purpose The efficacy of cisplatin, irinotecan, and bevacizumab was evaluated in patients with extensive-stage small-cell lung cancer (ES-SCLC). Patients and Methods Patients with ES-SCLC received cisplatin 30 mg/m2 and irinotecan 65 mg/m2 on days 1 and 8 plus bevacizumab 15 mg/kg on day 1 every 21 days for six cycles on this phase II study. The primary end point was to differentiate between 50% and 65% 12-month survival rates. Results Seventy-two patients were enrolled between March 2005 and April 2006; four patients canceled, and four were ineligible. Grade 3 or 4 toxicities included neutropenia (25%), all electrolyte (23%), diarrhea (16%), thrombocytopenia (10%), fatigue (10%), nausea (10%), hypertension (9%), anemia (9%), infection (7%), vascular access thrombosis (2%), stroke (2%), and bowel perforation (1%). Three deaths (5%) occurred on therapy as a result of pneumonitis (n = 1), stroke (n =1), and heart failure (n = 1). Complete response, partial response, and stable disease occurred in three (5%), 45 (70%), and 11 patients (17%), respectively. Progressive disease occurred in one patient (2%). Overall response rate was 75%. Median progression-free survival (PFS) was 7.0 months (95% CI, 6.4 to 8.4 months). Median overall survival (OS) was 11.6 months (95% CI, 10.5 to 15.1 months). Hypertension ≥ grade 1 was associated with improved OS after adjusting for performance status (PS) and age (hazard ratio [HR], 0.55; 95% CI, 0.31 to 0.97; P = .04). Lower vascular endothelial growth factor levels correlated with worse PFS after adjusting for age and PS (HR, 0.90; 95% CI, 0.83 to 0.99; P = .03). Conclusion PFS and OS times were higher compared with US trials in ES-SCLC with the same chemotherapy. However, the primary end point of the trial was not met. Hypertension was associated with improved survival after adjusting for age and PS.

Weekly paclitaxel and bevacizumab as fourth-line treatment or beyond for metastatic nonsquamous non-small cell lung cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e18066-e18066
Author(s):  
Stefanie Habib ◽  
Julie Delourme ◽  
Xavier Dhalluin ◽  
Arnaud Scherpereel ◽  
Jean-Jacques Lafitte ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Bowel Perforation ◽  
Small Cell ◽  
Weekly Paclitaxel ◽  
Line Treatment ◽  
Small Cell Lung ◽  
Line Therapy ◽  
Nsclc Patients

e18066 Background: Paclitaxel (P) and bevacizumab (B) showed synergistic antitumor efficacy in preclinical models. In combination with carboplatin, PB prolonged progression-free survival (PFS) and overall survival (OS) in selected metastatic non-squamous Non Small Cell Lung Cancer (NSCLC) patients compared to carboplatin and paclitaxel. Currently, there are no standard treatments beyond third-line therapy in NSCLC. We sought to determine the efficacy of weekly paclitaxel and bevacizumab (wPB) in non-squamous NSCLC as fourth-line therapy or beyond. Methods: we retrospectively reviewed patients with metastatic non-squamous NSCLC who have been treated with wPB in our institution. Patients were identified from a prospective database. Treatment consisted in P 80mg/m² on days 1, 8, 15 and B 15mg/kg on day 1, every 3 weeks until progression or unacceptable toxicity. Patients were evaluated every 3 cycles. PFS and OS were calculated from the date of initiation of wPB and analyzed using the Kaplan-Meier method. Results: Twenty patients received at least one cycle of wPB between 2008 and 2011. All patients received wPB as fourth-line treatment or beyond. Eight patients (40%) had a partial response, 7 patients (35%) had stable disease and 5 patients (25%) had progressive disease. Grade 3-4 adverse events included neutropenia (20%), onycholysis (10%), infection (10%), pulmonary haemorrhage (5%), neuropathy (5%) and hypertension (5%). One patient died from a bowel perforation following second cycle of wPB. The median PFS was 6.4 months (CI95% 4.1-9) and the median OS was 9.6 months (CI95% 7-19.7). One patient who previously received bevacizumab as part of first-line chemotherapy and another patient harbouring an ALK rearrangement benefited from wPB during more than 8 months and 18 months, respectively. Conclusions: In our experience, wPB exhibited acceptable toxicity and had encouraging anti-tumor efficacy as fourth-line treatment or beyond in non-squamous NSCLC patients, supporting further evaluation in larger prospective studies.

Evaluation of elderly patients with extended disease small-cell lung cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e18515-e18515 ◽  
Author(s):  
Tatiane Caldas Montella ◽  
Marina Mendes Vasco ◽  
Ana Licia Maia Silva ◽  
Morgana Stelzer Rossi ◽  
Carla Valéria Santos Sena ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Elderly Patients ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Performance Status ◽  
Small Cell ◽  
Small Cell Lung ◽  
Optimal Care ◽  
Cycle Number ◽  
Dismal Prognosis

e18515 Background: At diagnosis approximately 25-40% of patients with small cell lung cancer (SCLC) are over age 65 and more than 60% of them have extended disease (ED). There is a scarcity of data on this subpopulation. The aim of this study was to report clinical characteristics of this subpopulation, highlighting some challenges in their clinical management. Methods: In this retrospective cohort, data from 96 patients aged >65 years with SCLC diagnosed between 1997 and 2007 at a single institution were analyzed. Results: At diagnosis median age at presentation was 71, and most patients (n=65; 67.7%) had ED_SCLC and became the focus of our analysis. In this particular population the median survival time was 5 compared to 9 months for limited disease patients. Further, 63% of these patients had performance status (PS)≥2 and that was correlated with worse survival (PS0-1=9 months, PS2=4 months and PS3-4=3months; p=0.05). Additionally, 70% of this group with ED had at least one comorbidity and 30% had more than one. Of note, chemotherapy (CT) or radiotherapy (RT) were not administered in 23% of those patients, due to the lack of clinical conditions. CT was administered in 49 patients (75%), being carboplatin and etoposide the preferred regimen in contrast to cisplatin and etoposide (71 vs 28%). However, 44% of patients received less than 4 cycles of CT and 34% received only one cycle. Number of CT cycles were correlated with survival (1 cycle 1.5 months and 2-4cycles 8.7 months). Conclusions: Our data show that elderly patients with ED-SCLC constitutes a frail subpopulation, with poor PS and associated comorbidities, leading to suboptimal treatment and a dismal prognosis. Moreover, most of those patients were considered unfit for current treatment. These results highlight the urgent need for an individualized approach and clinical trials focused on elderly patients, in order to provide them an optimal care and improve their outcomes.

scholarly journals Multiple small bowel metastasis of primary non‐small cell lung cancer

2021 ◽  
Vol 9 (4) ◽  
pp. 1896-1898
Author(s):  
Do Kyun Kang ◽  
Min Kyun Kang ◽  
Woon Heo ◽  
Youn‐Ho Hwang ◽  
Kyung Han Nam
Keyword(s):  
Lung Cancer ◽  
Small Bowel ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Small Bowel Metastasis

Pemetrexed in patients (pts) with relapsed small cell lung cancer (SCLC): A phase II study from the Hoosier Oncology Group

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 7063-7063 ◽  
Author(s):  
N. H. Hanna ◽  
R. Ansari ◽  
S. Bhatia ◽  
R. Govindan ◽  
D. Bruetman ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Phase Ii Study ◽  
Single Agent ◽  
Primary Objective ◽  
Small Cell ◽  
Small Cell Lung ◽  
Dismal Prognosis

7063 Background: Patients with relapsed SCLC have a dismal prognosis. Pemetrexed is a well tolerated agent, which is active against non-small cell lung cancer. We postulated that Pemetrexed may also be active and well tolerated in pts with relapsed SCLC, for whom few effective options exist. Methods: Eligible pts had small cell or a poorly differentiated neuroendocrine cancer, received 1 or 2 prior chemotherapy regimens and had an ECOG PS 0–2. Pts received Pemetrexed 500 mg/m2 iv once every 3 weeks along with vitamin B12, folic acid, and dexamethasone for up to 6 cycles or progressive disease or intolerable side effects. Chemosensitive (S) pts (relapse > 90 days following 1st line chemo) and chemoresistant (R) pts (PD ≤ 90 days following 1st line chemo) were analyzed separately. The primary objective of this phase II study was to estimate the clinical benefit rate [partial response (PR) or stable disease (SD)] in the 2 populations. Pts were to be accrued in 2 stages. If 8 of 18 and 3 of 21 pts achieved a PR or SD in the S and R populations, respectively, accrual would have continued to a total of 46 (S arm) and 50 (R arm) pts in each arm. Results: From 1/05 to 9/05, 43 pts were enrolled. Criteria to proceed to stage II were not met for either arm. S arm (n = 20): M/F 12/8; median age 63 (range, 45–79), PS 0/1/2 7/8/5. R arm (n = 23): M/F 17/6; median age 65 (range, 42–79), PS 0/1/2 7/10/6. Select grade 3/4 toxicities (combined group): 4 pts with neutropenia; 2 pts each with anemia, AST/ALT, bilirubin elevation; 1 pt each with thrombocytopenia, febrile neutropenia, infection with neutropenia, and rash. S arm: 1 PR and 1 SD were confirmed. R arm: 1 PR and 1 SD were confirmed. Conclusions: Pemetrexed 500 mg/m2 has minimal single agent activity in pts with relapsed SCLC. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document